rs2275913 — IL17A -197G>A

IL-17A -197G>A: The Th17 Amplifier

Interleukin-17A (IL-17A) is the signature cytokine of Th17 cells¹¹ Th17 cells
a specialized subset of CD4+ T helper cells that drive inflammation at mucosal surfaces and in joints. Under normal conditions, Th17 cells defend against extracellular bacteria and fungi; when dysregulated, they become primary drivers of autoimmune inflammation in psoriasis, rheumatoid arthritis, ankylosing spondylitis, and inflammatory bowel disease. The rs2275913 (-197G>A) variant sits in the promoter of the IL17A gene and acts as a volume control for this entire inflammatory axis.

The Mechanism

The -197 position lies within a nuclear factor of activated T cells (NFAT) binding motif²² nuclear factor of activated T cells (NFAT) binding motif
NFAT is a transcription factor that, when active, drives IL-17A gene expression in stimulated T cells. The A allele increases the affinity of NFAT for this binding site compared to the G allele. When immune cells are activated — by infection, stress, gut dysbiosis, or autoimmune triggers — carriers of the A allele produce significantly more IL-17A than GG carriers. Reporter gene assays show the A allele construct has significantly higher luciferase activity than the G allele, especially under T-cell activation conditions. Electrophoretic mobility shift assays confirm that the A allele probe forms more intense protein-DNA complexes with NFAT than the G allele.

This variant location is also where vitamin D3 exerts its most direct effect on IL-17A. Active vitamin D (1,25-dihydroxyvitamin D3) represses IL-17A transcription by blocking NFAT at this exact binding site³³ Active vitamin D (1,25-dihydroxyvitamin D3) represses IL-17A transcription by blocking NFAT at this exact binding site
the vitamin D receptor competes with NFAT for occupancy at the -197 promoter element, recruits histone deacetylases, and sequesters Runx1. A allele carriers have enhanced baseline NFAT occupancy, making adequate vitamin D status particularly important for offsetting this elevated drive.

The Evidence

The functional consequences of increased IL-17A output have been documented across multiple diseases. In the largest functional study, PBMCs from A allele carriers secreted significantly higher IL-17 after stimulation, and donors with the A allele had a hazard ratio of 1.46 for acute graft-versus-host disease after unrelated bone marrow transplantation (Espinoza et al., PLoS ONE 2011, n=438 transplant pairs)⁴⁴ (Espinoza et al., PLoS ONE 2011, n=438 transplant pairs).

In ulcerative colitis, a Japanese case-control study of 202 UC patients and 475 controls showed the A allele minor allele frequency was significantly higher in cases, with the homozygous AA genotype conferring elevated UC risk, and combined rs2275913 AA / rs3748067 CC showing OR 3.38 (p=0.0007)⁵⁵ OR 3.38 (p=0.0007).

In ovarian endometriosis, a Chinese case-control study (316 patients, 328 controls) found AA genotype associated with OR 2.28 (95% CI 1.37–3.80) vs GG⁶⁶ AA genotype associated with OR 2.28 (95% CI 1.37–3.80) vs GG, with elevated IL-17A mRNA confirmed in ectopic endometrial tissue of AA carriers.

A 2023 meta-analysis of recurrent miscarriage found the AA genotype significantly associated with recurrent pregnancy loss (OR 1.68, 95% CI 1.13–2.49)⁷⁷ (OR 1.68, 95% CI 1.13–2.49).

For coronary artery disease, a case-control study showed the AA genotype conferred OR 2.42 (95% CI 1.26–4.54)⁸⁸ OR 2.42 (95% CI 1.26–4.54) for CAD development, with elevated serum IL-17A levels in cases.

Practical Actions

Three interventions specifically target the Th17/IL-17A axis and are relevant to A allele carriers:

Vitamin D3: Active vitamin D is the most direct molecular antagonist of the NFAT site where this variant acts. Maintaining serum 25(OH)D above 40 ng/mL (100 nmol/L) is the target for Th17 modulation. Most adults require 2,000–4,000 IU D3 daily to reach this level; those with dark skin, limited sun exposure, or VDR variants may need more. Test serum 25(OH)D to calibrate your dose.

EPA/DHA omega-3s: EPA suppresses Th17 polarization and reduces IL-17A production through prostaglandin D3 (PGD3), an EPA-derived metabolite that inhibits Th17 differentiation and promotes Treg expansion. Studies in psoriasis models show EPA normalizes keratinocyte hyperproliferation and reduces IL-17A output. Aim for 2–3 g combined EPA/DHA daily from fish oil or algae-based supplements.

Probiotics: Specific strains shift the Th17/Treg balance. Lactobacillus acidophilus, L. rhamnosus, L. delbrueckii, and Bifidobacterium breve have been shown to reduce Th17 polarization and IL-17 production, while expanding regulatory T cells. A randomized controlled trial in asthma patients showed multi-strain probiotic supplementation significantly reduced Th17-related IL-17 and IL-6.

Three FDA-approved biologics now target IL-17A directly: secukinumab (Cosentyx), ixekizumab (Taltz), and bimekizumab (Bimzelx). If you develop psoriasis, ankylosing spondylitis, or psoriatic arthritis, your AA or AG genotype may predict particularly strong response to these drugs compared to older anti-TNF agents, since IL-17A is the direct driver of your inflammatory phenotype.

Interactions

The rs2275913 promoter variant acts synergistically with rs3748067⁹⁹ rs3748067
another IL17A promoter variant at the +1044C>T position in ulcerative colitis risk. The combination of rs2275913 AA and rs3748067 CC creates a 3.38-fold UC risk, substantially higher than either variant alone. Both should be interpreted together for gut inflammation risk.

The related cytokine gene IL17F rs763780¹⁰¹⁰ IL17F rs763780
F allele reduces IL-17F bioactivity and actually blunts inflammatory signaling — users with the IL-17A risk (rs2275913 A) combined with functional IL-17F (rs763780 GG) have the highest net Th17 output.

Downstream, PTPN22 rs2476601¹¹¹¹ PTPN22 rs2476601
a phosphatase variant that dysregulates T cell activation thresholds interacts with IL-17A pathway variants to compound autoimmune susceptibility — carriers of both should be especially attentive to early autoimmune symptoms.

The vitamin D receptor pathway variants (VDR rs2228570) influence how effectively vitamin D can suppress the NFAT binding at the IL-17A promoter — if VDR function is also impaired, higher vitamin D doses may be needed to achieve equivalent Th17 suppression.